REGULATORY

MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis

June 26, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) has withdrawn its sakigake fast-track designation for Takeda Pharmaceutical’s proteasome inhibitor Ninlaro (ixazomib) for the treatment of immunoglobulin light chain amyloidosis (AL amyloidosis) after the company called off the program. The MHLW…

To read the full story

Takeda Updates Failed Ninlaro Trial Results for Amyloidosis
December 10, 2019
Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019

REGULATORY

Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
LDP Panel Delays Approval of Health Insurance Bill amid Concerns over OTC-Like Drug Charges
February 26, 2026
MHLW Orders Colchicine Label Revision, Warns against Doses above 1.5 mg per Day
February 26, 2026
Symbicort Switch to OTC Status Gains No Support at MHLW Panel
February 25, 2026
Japan Govt Council Finalizes Recommendations for National MCM Strategy
February 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…